Beyond monoclonal antibodies: New therapeutic agents in non-Hodgkin's lymphomas

Oncologist

Volumn 14, Issue 5, 2009, Pages 511-525

  Delmonte, Angelo ^a   Ghielmini, Michele ^a   Sessa, Cristiana ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Molecular pathways; New drugs; Non Hodgkin's lymphoma; Targeted therapies

Indexed keywords

ABT 263; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CARFILZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFOROLIMUS; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; IPSI 001; LENALIDOMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; OBATOCLAX; OBLIMERSEN; PR 171; PREDNISONE; RAPAMYCIN; RITUXIMAB; SALINOSPORAMIDE A; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ADVANCED CANCER; ANEMIA; ANOREXIA; ASTHENIA; ATAXIA; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHROMATURIA; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EUPHORIA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LUNG EMBOLISM; LYMPHOBLASTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; SOMNOLENCE; SWEATING; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOMA, NON-HODGKIN; OLIGONUCLEOTIDES, ANTISENSE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE C; PYRAZINES; SIROLIMUS;

EID: 66349088580     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0214     Document Type: Review

References (133)

1. Nencioni A, Grünebach F, Patrone F et al. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007;21:30-36. (Pubitemid 44921831)
2. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-4789. (Pubitemid 46224082)
3. Nakayama KI, Nakayama K. Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-381.
4. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
5. Kane RC, Dagher R, Farrell A et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291-5294. (Pubitemid 47510352)
6. Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-4297. (Pubitemid 47548570)
7. Belch A, Kouroukis CT, Crump M et al. A phase II study of Bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-121. (Pubitemid 46152510)
8. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874. (Pubitemid 46655613)
9. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib chemotherapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-2112. (Pubitemid 46622122)
10. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-684. (Pubitemid 46237441)
11. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675. (Pubitemid 46224166)
12. Dimopoulos MA, Gertz MA, Kastritis E et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's macroglobulinemia. J Clin Oncol 2009;27:120-126.
13. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-179.
14. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008;14:1649-1657.
15. Aghajanian CA, Hamlin P, Gordon MS et al. Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors. J Clin Oncol 2008;26(15 suppl):Abstract 3574.
16. Stewart KA, O'Connor OA, Alsina M et al. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 2007;25(18 suppl):Abstract 8003.
17. Kuhn DJ, Hunsucker SA, Chen Q et al. Targeted inhibition of immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and non-specific proteasome inhibitors. Blood 2008; Dec 2 [Epub ahead of print].
18. Menhert JM, Kelly WK. Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J 2007;13:23-29.
19. Shaffer AL, Yu X, He Y et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
20. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216. (Pubitemid 30627729)
21. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588. (Pubitemid 37169221)
22. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931. (Pubitemid 46218695)
23. Olsen EA, Kim YH, Kuzel TM et al. Phase IIB multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115. (Pubitemid 47218059)
24. Crump M, Andreadis C, Assouline S et al. Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. J Clin Oncol 2008;26(15 suppl):Abstract 8528.
25. Bociek RG, Kuruvilla J, Pro B et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J Clin Oncol 2008;26(15 suppl):Abstract 8507.
26. O'Connor OA. New drugs for the treatment of T-cell lymphoma. Ann Oncol 2008;19(suppl 4).
27. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-515. (Pubitemid 26271704)
28. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221. (Pubitemid 26122649)
29. Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-386. (Pubitemid 29295864)
30. Haslett PA, Corral LG, Albert M et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+subset. J Exp Med 1998; 187:1885-1982. (Pubitemid 28262451)
31. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
32. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15:1950-1961. (Pubitemid 33115003)
33. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525-4530. (Pubitemid 34627223)
34. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436. (Pubitemid 46630462)
35. Pro B, Younes A, Albitar M et al. Thalidomide for patients with recurrent lymphoma. Cancer 2004;100:1186-1189. (Pubitemid 38325946)
36. Kaufmann H, Raderer M, Wöhrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-2271. (Pubitemid 39331822)
37. Chanan-Khan AD, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552.
38. List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557. (Pubitemid 40204668)
39. Weber D, Chen C, Niesviyky R et al. Lenalidomide plus high-dose dexamethasone versus dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of North American phase III study (MM-009). J Clin Oncol 2006;24:427s.
40. Dimopoulos MA, Spenser A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of phase III study (MM-010). Proc Am Soc Hematol 2005;106:6.
41. Corral L, Zhu D, Wang Y et al. The ImiDs immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce growth arrest and apoptosis in NHL tumor cells in vitro. Blood 2006;108:Abstract 2388.
42. Wu L, Schafer P, Muller G et al. Lenalidomide strongly enhances natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) of rituximab treated non-Hodgkin lymphoma cell lines in vitro. Blood 2006;108:Abstract 3714.
43. Witzig TE, Vose J, Pietronigro K et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin Lymphoma. J Clin Oncol 2007;25(18 suppl):Abstract 8066.
44. Wang M, Fayad L, Hagemeister F et al. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 2007;25(18 suppl): Abstract 8030.
45. Vignot S, Faivre S, Aguirre D et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537. (Pubitemid 40613318)
46. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-6414. (Pubitemid 46222241)
47. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br j Haematol 2004;124:130-140. (Pubitemid 38122184)
48. Kurtin PJ. Mantle cell lymphoma. Adv Anat Pathol 1998;5:376-398.
49. Kurtin PJ, Hobdaz KS, Yiesmer S et al. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Pathol 1999;112:319-329. (Pubitemid 30214770)
50. Lee VW, Chapman JR. Sirolimus: Its role in nephrology. Nephrology (Carlton) 2005;10:606-614.
51. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323. (Pubitemid 40411498)
52. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-5356. (Pubitemid 46206988)
53. Hess G, Romaguera JE, Verhoef G et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 2008;26(15 suppl): Abstract 8513.
54. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 2007;33:78-84. (Pubitemid 46132007)
55. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858. (Pubitemid 37025404)
56. Lorber MI, Mulgaonkar S, Butt KM et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-252. (Pubitemid 41061682)
57. Reeder CB, Gornet MK, Habermann TM et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non- Hodgkin lymphoma. Blood 2007;110:Abstract 121.
58. Rizzieri DE, Feldman E, DiPersio JF et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-2762.
59. Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326. (Pubitemid 28406819)
60. Webb A, Cunningham D, Cotter F et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-1141. (Pubitemid 27168548)
61. Hanada M, Delia D, Aiello A et al. bcl-2 gene hypomethylation and highlevel expression in B-cell chronic lymphocytic leukemia. Blood 1993;82: 1820-1828. (Pubitemid 23278773)
62. Cotter FE. Antisense therapy of hematologic malignancies. Semin Hematol 1999;36(suppl 6):9-14. (Pubitemid 29489655)
63. Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacological study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-1823. (Pubitemid 30261918)
64. Leonard JP, Coleman M, Vose J et al. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma. Proc Am Soc Clin Oncol 2003;22:2276.
65. O'Brien S, Claxton DF, Crump M et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113: 299-305.
66. Elmore S. ABT-263: An orally bioavailable Bcl-2 family protein inhibitor. Presented at the 98th American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007.
67. Wilson WH, Czuczman MS, LaCasce AS et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol 2008;26(15 suppl):Abstract 8511.
68. Morimoto RI, Kline MP, Bimston DN et al. The heat-shock response: Regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 1997;32:17-29. (Pubitemid 127470399)
69. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: From nascent to folded protein. Science 2002;295:1852-1858.
70. Takayama S, Reed JC, Homma S et al. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-9047. (Pubitemid 38121704)
71. Burrows F, Zhang H, Kamal A et al. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-1536. (Pubitemid 40521406)
72. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-217. (Pubitemid 37443877)
73. Valbuena JR, Rassidakis GZ, Lin P et al. Expression of heat-shock protein- 90 in non-Hodgkin's lymphomas. Mod Pathol 2005;18:1343-1349. (Pubitemid 41348653)
74. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17- AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71. (Pubitemid 44337664)
75. Mimnaugh EG, Xu W, Vos M et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-566. (Pubitemid 39193734)
76. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspective for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762. (Pubitemid 47463673)
77. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 2004;4:125-146. (Pubitemid 38332552)
78. Castagna M, Takai Y, Kaibuchi K et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982;257:7847-7851. (Pubitemid 12043279)
79. Chang PL, Chambers AF. Transforming JB6 cells exhibit integrin-mediated adhesion to osteopontin. J Cell Biochem 2000;78:8-23. (Pubitemid 30346379)
80. Park MJ, Park IC, Hur JH et al. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 200;290:201-204. (Pubitemid 30645867)
81. Fang X, Yu S, Tanyi JL et al. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase Cdependent intracellular pathway. Mol Cell Biol 2002;22:2099-2110. (Pubitemid 34224618)
82. Murray NR, Davidson LA, Chapkin RS et al. Overexpression of protein kinase C βII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711. (Pubitemid 29240849)
83. Black JD. Protein kinase C isozymes in colon carcinogenesis: Guilt by omission. Gastroenterology 2001;120:1868-1872. (Pubitemid 32523504)
84. Suga K, Sugimoto I, Ito H et al. Down-regulation of protein kinase Calpha detected in human colorectal cancer. Biochem Mol Biol Int 1998; 44:523-528. (Pubitemid 28143818)
85. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74. (Pubitemid 34101731)
86. Faul MM, Gillig JR, Jirousek MR et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: Isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857-1859. (Pubitemid 36577128)
87. Graff JR, McNulty AM, Hanna KR et al. The protein kinase C β-selective inhibitor, enzastaurin (LZ317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-7469. (Pubitemid 41161281)
88. Hanauske A, Oberschmidt O, Hanauske-Abel H et al. Antitumor activity of enzastaurin (LYZ317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro soft-agar cloning experiments. Invest New Drugs 2007;25:205-210. (Pubitemid 46774707)
89. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: Correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-820. (Pubitemid 38519759)
90. Querfeld C, Rizvi MA, Kuzel TM et al. The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-1647. (Pubitemid 43910381)
91. Robertson MJ, Kahl BS, Vose JM et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-1746. (Pubitemid 46797955)
92. Morschhauser F, Seymour JF, Kluin-Nelemans HC et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-253.
93. Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 2000;8:1841-1860. (Pubitemid 30612475)
94. Hornung RL, Pearson JW, Beckwith M et al. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity. Cancer Res 1992;52:101-107.
95. Grant S, Pettit GR, Howe C et al. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor. Leukemia 1991;5:392-398.
96. Berkow RL, Schlabach L, Dodson R et al. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 1993;53:2810-2815.
97. Berkow RL, Kraft AS. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985;131:1109-1116. (Pubitemid 16234299)
98. Bosco MC, Rottschafer S, Taylor LS et al. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2Rγ chain expression. Blood 1997;89:3402-3411. (Pubitemid 27229828)
99. Tallant EA, Smith JB, Wallace RW. Bryostatins mimic the effects of phorbol esters in intact human platelets. Biochim Biophys Acta 1987; 929:40-46. (Pubitemid 17084445)
100. McCrady CW, Staniswalis J, Pettit GR et al. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. Br J Haematol 1991;77: 5-15.
101. May WS, Sharkis SJ, Esa AH et al. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A 1987;84:8483-8487. (Pubitemid 18033455)
102. Prendiville J, Crowther D, Thatcher N et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993;68:418-424. (Pubitemid 23229449)
103. Philip PA, Rea D, Thavasu P et al. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993;85:1812-1818.
104. Jayson GC, Crowther D, Prendiville J et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995;72:461-468.
105. Varterasian ML, Mohammad RM, Eilender DS et al. Phase I bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998;16:56-62. (Pubitemid 28041579)
106. Blackhall FH, Ranson M, Radford JA et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 2001;84:465-469. (Pubitemid 32215870)
107. Vrana JA, Wang Z, Rao AS et al. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): Interactions with the macrocyclic lactone bryostatin 1. Leukaemia 1999;13:1046-1055.
108. Roberts JD, Smith MR, Feldman EJ et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res 2006;12:5809-5816. (Pubitemid 44629613)
109. Bellamy WT, Richter L, Frugiter Y et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733. (Pubitemid 29076074)
110. Gille H, Kowalski J, Li B et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-3230. (Pubitemid 37411615)
111. Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-17634. (Pubitemid 26250731)
112. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
113. Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol 2005;16:999-1004.
114. Salven P, Orpana A, Teerebhovi L et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: A single-institution study of 200 patients. Blood 2000;96:3712-3718.
115. Hazar B, Paydas S, Zorludemir S et al. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:2089-2093. (Pubitemid 37369649)
116. Streubel B, Chott A, Huber D et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250-259. (Pubitemid 38916042)
117. Wang ES, Teruya-Feldstein J, Wu Y et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-2902. (Pubitemid 39434977)
118. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
119. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-2676.
120. Manegold C, von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with paclitaxel and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25(18 suppl):LBA7514.
121. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
122. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26: 60-65.
123. Stopeck AT, Bellamy W, Unger J et al. Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol 2005;23(16 suppl):Abstract 6592.
124. Ganjoo KN, An CS, Robertson MJ et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998-1005.
125. Gandhi V. Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies. Semin Oncol 2002;29(suppl 13):4-11.
126. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs 2001;12:725-729. (Pubitemid 33001185)
127. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26:204-210.
128. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 4473-4479.
129. Rummel MJ, von Gruenhagen U, Niederle N et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study of the study group indolent lymphomas (StiL). Blood 2008;112:Abstract 2596.
130. Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione- induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995;50:1087-1094.
131. Beggiolin G, Crippa L, Menta E et al. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001;87:407-416.
132. Borchmann P, Schnell R, Knippertz R et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661-667. (Pubitemid 32519919)
133. Borchmann P, Morschhauser F, Parry A et al. Phase-II study of the new aza-anthracenedione, BBR2778, in patients with relapsed aggressive non- Hodgkin's lymphomas. Haematologica 2003;88:888-894. (Pubitemid 37128088)